Aridis Pharmaceuticals (ARDS) Announces Earnings Results, Misses Estimates By $0.12 EPS

Aridis Pharmaceuticals (NASDAQ:ARDS) announced its quarterly earnings results on Tuesday. The company reported ($0.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.87) by ($0.12), Fidelity Earnings reports. The company had revenue of $1.02 million for the quarter.

Shares of NASDAQ:ARDS opened at $9.76 on Wednesday. Aridis Pharmaceuticals has a 12-month low of $7.59 and a 12-month high of $13.85. The company has a market cap of $77.59 million and a price-to-earnings ratio of -1.39.

ARDS has been the topic of a number of research reports. Northland Securities reiterated a “buy” rating and issued a $40.00 price target on shares of Aridis Pharmaceuticals in a research note on Wednesday, April 17th. Zacks Investment Research upgraded shares of Aridis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a research note on Tuesday, April 2nd. Finally, Maxim Group restated a “buy” rating and set a $25.00 target price on shares of Aridis Pharmaceuticals in a research report on Monday, April 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $27.50.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at

About Aridis Pharmaceuticals

Aridis Pharmaceuticals Inc, a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S.

Further Reading: Short Selling Stocks, A Beginner’s Guide

Receive News & Ratings for Aridis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aridis Pharmaceuticals and related companies with's FREE daily email newsletter.